We observe that BAP1-deficient human mesothelioma cell lines (except H28) are hypersensitive to the combined treatment of EZH2 inhibitor GSK126 and mevalonate pathway inhibitor ZA (Figures 4A and S4A–S4J). Here, EZH2 is linked to mesothelioma.